James Brumley

James Brumley

James Brumley is a reformed stock broker and former Director of Research for an options-focused newsletter. He’s now primarily a freelance writer, tapping more than a decade’s worth of broad experience to help investors get more out of the market.

With a background in technical analysis as well as fundamental analysis, James writes with a multifaceted philosophy that combines the importance of company performance with the power of stock-trade timing. His commentary is as apt to focus on a chart as it is earnings, as he believes this dual approach is the only way an investor has a shot at consistently beating the market.

James’ work has appeared at several websites, including Street Authority, Motley Fool, Kapitall and Investopedia. When not writing as a journalist, James works on his book explaining his multipronged approach to investing.

Recent Articles

Tesla Motors Inc (TSLA): Elon Musk’s Confessions Are Just What Tesla Needs

Owners of Tesla stock have seen and heard a lot of things over the years, but Tuesday's TSLA shareholder meeting was something refreshing.

Why Banco Bradesco SA (ADR) (BBD), Coca-Cola Enterprises Inc (CCE) and Great Plains Energy Incorporated (GXP) Are Three of Today’s Worst Stocks

Banco Bradesco (BBD), Coca-Cola (CCE) and Great Plains Energy (GXP) got the new trading week started on the wrong foot.

10 Biotech Stocks With Symptoms of Strong Growth

Most sectors are overextended and ripe for weakness, but biotech stocks are the exception. Put these names on your list of stocks to buy this summer.

Valeant Pharmaceuticals Intl Inc: VRX May Not Be a Lost Cause After All

Valeant Pharmaceuticals (VRX) may be wounded, but it's not dead yet. A team of suitors expressed interest in the company a few weeks ago.

Abercrombie & Fitch Co.: It’s Time for ANF to Face the Music

The once-iconic Abercrombie & Fitch (ANF) may be beyond salvaging at this point. It's time to go back to the drawing board.